Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
ID: 357911Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357911
Timeline
    Description

    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Notice of Funding Opportunity for Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer’s Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer’s disease (AD) and related dementias (ADRD). This initiative seeks applications for promising pharmacological and non-pharmacological strategies that may prevent, delay, or treat the symptoms of AD, utilizing the ACTC's trial coordination and management infrastructure. The NOFO is significant as it addresses a critical health challenge, and it is expected to be published in December 2024, with application due dates in March, June, and October of 2025. Interested applicants should prepare for the R01 activity code funding, with an estimated award date set for December 1, 2025.
    Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for early and late-stage clinical trials focused on Alzheimer's Disease (AD) and related dementias, as well as age-related cognitive decline. This initiative aims to develop and implement both pharmacological and non-pharmacological interventions to address cognitive and neuropsychiatric changes associated with these conditions, while also encouraging innovative trial designs and methodologies. Given the significant public health crisis posed by AD, which currently affects over six million Americans, this funding opportunity is part of a broader strategy to enhance research and develop effective therapies across the disease spectrum. Applications are due by January 7, 2025, and interested parties can find more information and submit proposals through the NIH ASSIST online system or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity for Centers on the Demography and Economics of Aging and Alzheimer�s Disease and Alzheimer�s Disease Related Dementias Coordinating Center (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Coordinating Center focused on the Demography and Economics of Aging, including Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD). The objective of this cooperative agreement is to create a hub that facilitates collaboration among various D&E Centers, scholars, and the research community, enhancing the scientific impact and fostering synergies across related programs and infrastructures. This initiative is crucial for promoting an inclusive research environment and raising awareness about the demography and economics of aging. The estimated total program funding is $1,320,000, with an award ceiling of $800,000, and the application process is expected to open in July 2024, with submissions due by October 2024. Interested applicants should prepare to develop meaningful collaborations in advance of the application deadline.
    Notice of Intent to Publish a Funding Opportunity Announcement for Deriving Common Data Elements from Real-World Data for Alzheimer�s Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at developing Common Data Elements (CDEs) for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) utilizing Real-World Data (RWD) from electronic health records and CMS claims. The objective is to enhance data harmonization and interoperability among disparate RWD systems, thereby facilitating more efficient research and faster production of real-world evidence. This funding opportunity, categorized as a cooperative agreement, has an estimated total program funding of $4 million, with a maximum award ceiling of $2.5 million, and is expected to result in one award. Interested applicants should prepare for the anticipated application due date in June 2024, following the expected publication of the NOFO in March 2024.
    Notice of Intent to Publish a Notice of Funding Opportunity for Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D&E Centers) (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the development or renewal of Research and Development Centers (P30) focused on the demography and economics of aging, particularly concerning Alzheimer’s disease and related dementias (AD/ADRD). The program aims to seed innovative research, integrate health disparity approaches, and engage a diverse range of scholars across disciplines, providing a structured support system for pilot projects and data sharing. With an estimated total program funding of $9 million and an award ceiling of $600,000, the NOFO is expected to be published in July 2024, with applications due by October 2024 and awards anticipated by June 2025. Interested applicants are encouraged to prepare collaborative proposals in advance of the application period.
    Notice of Intent to Publish a Notice of Funding Opportunity for Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing research on biomarkers of cognitive decline and dementias in individuals on the Autism Spectrum. This initiative seeks to conduct observational studies utilizing deep phenotyping techniques, including neuroimaging and molecular approaches, to identify and characterize neurodegeneration biomarkers in this population, as well as to evaluate existing dementia biomarkers in the context of Autism Spectrum Disorders (ASD). The total estimated funding for this program is $5 million, with the NOFO expected to be published in December 2024 and applications due by February 2025, leading to awards anticipated by September 2025. Interested applicants are encouraged to prepare collaborative proposals in advance of the official announcement.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.